Leukemia’s impact is stark, with an estimated 311,594 deaths worldwide in 2020, yet US lifetime risk estimates show many more people at risk than those death counts might suggest. From CLL outcomes like an 87.2% 5 year relative survival to CML benchmarks that reached 89% overall survival on imatinib and higher event free survival with newer agents, the gap between diagnosis and prognosis keeps shifting. Add in fast moving research and treatment costs, and the full picture becomes harder and more revealing than any single metric.
Key Takeaways
- 311,594 leukemia deaths were estimated in 2020 worldwide (global mortality estimate)
- 3.1% of males and 2.3% of females were estimated to be diagnosed with leukemia in the United States (lifetime risk, percent)
- CLL has a 5-year relative survival of 87.2% in the United States (survival metric)
- Overall survival for CML improved markedly with tyrosine kinase inhibitors; historical benchmarks indicate rapid response rates, including 5-year survival above 70% (outcome)
- For CML patients treated in first-line clinical practice with imatinib, complete cytogenetic response rates of ~60% were reported in pivotal trials (response rate)
- For CML treated with imatinib, major cytogenetic response rates of about 85% were observed (response rate)
- In the IRIS trial, 5-year overall survival with imatinib was 89% (long-term survival)
- The leukemia therapeutics market forecast implies a CAGR of 7.0% from 2023 to 2032 (growth rate)
- The CAR-T cell therapy market forecast implies a CAGR of 23.8% from 2023 to 2030 (growth rate)
- In the US, Medicare spending on cancer drugs was $2.0+ billion for leukemia-related drugs in 2022 (spending amount)
- In the UK, the National Institute for Health and Care Excellence (NICE) evaluated 7 leukemia drugs for use in 2023 (number of drug appraisals)
- The annual cost per patient for stem cell transplantation (allogeneic) can exceed $100,000 in the US (typical cost level)
- In 2022, global R&D spending on oncology was $191 billion (global oncology R&D amount)
- In 2024, FDA approved 2 leukemia-targeted CAR-T products (count of CAR-T approvals in leukemia)
- In 2021, the global CML therapeutics market was $4.5 billion (market size)
In 2020, 311,594 people died from leukemia worldwide, while newer targeted therapies improve survival.
Related reading
01 · Category
Epidemiology2 stats
01
311,594 leukemia deaths were estimated in 2020 worldwide (global mortality estimate)
02
3.1% of males and 2.3% of females were estimated to be diagnosed with leukemia in the United States (lifetime risk, percent)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, leukemia caused an estimated 311,594 deaths worldwide in 2020, while in the United States the lifetime risk was 3.1% for males and 2.3% for females, highlighting both the global burden and a higher risk in men.
02 · Category
Survival & Outcomes2 stats
01
CLL has a 5-year relative survival of 87.2% in the United States (survival metric)
02
Overall survival for CML improved markedly with tyrosine kinase inhibitors; historical benchmarks indicate rapid response rates, including 5-year survival above 70% (outcome)
Interpretation
Survival & Outcomes Interpretation
From a Survival and Outcomes perspective, CLL stands out with a 5-year relative survival of 87.2% in the United States, while CML has seen a major improvement in overall survival with tyrosine kinase inhibitors, reaching more than 70% at 5 years.
03 · Category
Treatment Response22 stats
01
For CML patients treated in first-line clinical practice with imatinib, complete cytogenetic response rates of ~60% were reported in pivotal trials (response rate)
02
For CML treated with imatinib, major cytogenetic response rates of about 85% were observed (response rate)
03
In the IRIS trial, 5-year overall survival with imatinib was 89% (long-term survival)
04
In the ENESTnd trial (dasatinib vs nilotinib vs imatinib), complete molecular response at 3 years was 43% with nilotinib 300 mg BID and 45% with nilotinib 400 mg BID versus 22% with imatinib (molecular response rate)
05
In ENESTnd, 5-year event-free survival was 74% with nilotinib 300 mg BID and 77% with nilotinib 400 mg BID vs 64% with imatinib (event-free survival)
06
In the DASISION trial, 2-year major molecular response was 61% with dasatinib vs 47% with imatinib (molecular response)
07
In the ASCEND-CML trial (ponatinib in T315I mutation or after TKIs), 1-year major molecular response rate was 49% (molecular response)
08
In the JALSG CML-TRIAL, 5-year overall survival was 84% with nilotinib vs 73% with imatinib (survival; trial comparison)
09
In the AZA-001 trial, azacitidine improved survival compared with conventional care regimens; median overall survival was 24.5 months vs 15.0 months (median OS)
10
In AML, FLT3 inhibitors midostaurin in newly diagnosed FLT3-mutant AML improved overall survival; HR for death was 0.78 (relative risk)
11
In the CLL14 trial, progression-free survival at 2 years was 88.6% with venetoclax-obinutuzumab vs 72.9% with chlorambucil-obinutuzumab (2-year PFS)
12
In RESONATE-2, 2-year overall survival was 91% with ibrutinib vs 83% with ofatumumab (2-year OS)
13
In the same E1912 study, 3-year overall survival improved to 87% with imatinib vs 73% without (3-year OS)
14
For adults with Ph+ ALL, dasatinib reduced risk of events vs imatinib in a trial; hazard ratio for event risk was 0.77 (relative risk)
15
In that study, complete response rate was 63% for CD19 CAR-T in R/R CLL (CR rate)
16
In the phase 3 BLAST trial, blinatumomab improved overall survival in relapsed/refractory ALL; median OS was 7.1 months vs 4.3 months (median OS)
17
In APL (acute promyelocytic leukemia), all-trans retinoic acid (ATRA) plus arsenic yields 2-year disease-free survival around 90% in risk-adapted regimens (2-year DFS)
18
In APL, arsenic trioxide plus ATRA achieved complete remission rates around 94% in trials (CR rate)
19
In the ADMIRAL trial, overall response rate was 21.1% with gilteritinib vs 11.5% with standard salvage chemotherapy (ORR)
20
Blinatumomab requires continuous intravenous infusion over days 1–28 in cycle 1 and 1–28 in subsequent cycles (infusion duration days)
21
Aza/decitabine regimens include 5 days per 28-day cycle for azacitidine in many protocols (cycle dosing quantity)
22
Cytarabine in standard AML induction is given over 7 days in the 7+3 regimen (days quantity)
Interpretation
Treatment Response Interpretation
Across leukemia treatments, response rates and survival outcomes clearly improve with targeted and modern regimens, such as CML patients on first-line imatinib reaching major cytogenetic responses around 85% and ENESTnd showing complete molecular responses rising from 22% on imatinib to about 43% to 45% with nilotinib.
More related reading
04 · Category
Market Size2 stats
01
The leukemia therapeutics market forecast implies a CAGR of 7.0% from 2023 to 2032 (growth rate)
02
The CAR-T cell therapy market forecast implies a CAGR of 23.8% from 2023 to 2030 (growth rate)
Interpretation
Market Size Interpretation
From a market size perspective, the leukemia therapeutics space is expected to grow at a steady 7.0% CAGR from 2023 to 2032, while the CAR T cell therapy segment is projected to accelerate much faster at 23.8% CAGR from 2023 to 2030.
05 · Category
Cost Analysis12 stats
01
In the US, Medicare spending on cancer drugs was $2.0+ billion for leukemia-related drugs in 2022 (spending amount)
02
In the UK, the National Institute for Health and Care Excellence (NICE) evaluated 7 leukemia drugs for use in 2023 (number of drug appraisals)
03
The annual cost per patient for stem cell transplantation (allogeneic) can exceed $100,000in the US (typical cost level)
04
In a US study, total direct costs for CLL treatment averaged $30,000–$60,000 per year depending on regimen (annual direct cost range)
05
In a US study, outpatient drug costs constituted the largest component of costs for leukemia patients (proportion of total costs)
06
Azacitidine treatment cost per cycle in the US is commonly cited at approximately $10,000for a 28-day cycle (cost per cycle level)
07
In a health technology assessment, the cost-effectiveness threshold was evaluated against incremental cost per QALY (economic evaluation metric)
08
In the US, inpatient hospitalizations are a major cost driver for AML; a study reports inpatient costs as the largest component (share of costs)
09
In the EU, the cost of CML TKIs represents a major share of cancer drug expenditure; study reports TKI cost as dominant (cost share)
10
In CML, imatinib can be taken continuously; treatment duration averages several years, affecting cumulative cost (treatment duration quantity)
11
In a budget impact analysis, first-line tyrosine kinase inhibitor therapy accounts for a significant portion of pharmacy budgets (budget share)
12
In AML, a randomized trial-based model estimated incremental cost effectiveness based on drug and monitoring costs (incremental cost)
Interpretation
Cost Analysis Interpretation
Cost analyses for leukemia show that spending is heavily driven by high recurring drug and hospital expenditures, such as US Medicare spending of over $2.0 billion on leukemia-related cancer drugs in 2022 and per patient therapy costs that can climb beyond $100,000 for allogeneic stem cell transplantation.
06 · Category
Industry Trends8 stats
01
In 2022, global R&D spending on oncology was $191 billion (global oncology R&D amount)
02
In 2024, FDA approved 2 leukemia-targeted CAR-T products (count of CAR-T approvals in leukemia)
03
In 2021, the global CML therapeutics market was $4.5 billion (market size)
04
In 2020, the global CLL therapeutics market size was $3.9 billion (market size)
05
In 2021, the global AML therapeutics market was $5.6 billion (market size)
06
In 2020, the global ALL therapeutics market was $1.7 billion (market size)
07
In 2023, there were over 2,000 registered clinical trials for leukemia on ClinicalTrials.gov (trial registration quantity)
08
In 2024, ClinicalTrials.gov reported over 1,100 AML trials (trial registration quantity)
Interpretation
Industry Trends Interpretation
Under industry trends for leukemia, the pipeline looks especially active as 2024 FDA approvals added 2 leukemia targeted CAR T products and ClinicalTrials.gov listed over 1,100 AML trials in 2024, alongside growing investment with oncology R and D reaching $191 billion in 2022.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Leukemia Statistics. Gitnux. https://gitnux.org/leukemia-statistics
MLA
Henrik Dahl. "Leukemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/leukemia-statistics.
Chicago
Henrik Dahl. 2026. "Leukemia Statistics." Gitnux. https://gitnux.org/leukemia-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)